Optiscan has been featured in Stockhead, The Australian, and 11 News Corp mastheads regarding Optiscan’s role in revolutionizing digital pathology and real-time cancer diagnosis.

The piece explores how Optiscan’s miniaturized confocal endomicroscope is transforming traditional pathology by enabling high-resolution imaging directly from tissue, eliminating the need for biopsies and enhancing surgical precision.

The article also details Optiscan’s strategic collaborations, including a five-year research agreement with the University of Minnesota to explore veterinary applications and a partnership with the Mayo Clinic to develop imaging technology for robotic-assisted surgery. Additionally, it covers Optiscan’s work with Monash University on an AI-driven gastrointestinal endomicroscope and its upcoming clinical studies in breast cancer surgery.

Commenting on Optiscan’s impact, CEO Dr. Camile Farah stated, “We are proud of Optiscan’s innovative technology and continue to transform the surgical oncology and digital pathology landscapes for the benefit of patients globally.”

Stockhead – Read the full article here.
The Australian – Read the full article here.